Seriously, some of you people are full of it. Of course, if you...

Seriously, some of you people are full of it. Of course, if you are reading this, that comment does not apply to you, but to the other commenters in the thread.

It is astounding it went up to 305 on this run in the first place as it did 3 successive 5 subwave cycles as part of a wave 1. After that it completes a major wave 1 (ie. now) a stock will almost always (like 90% of the time) retrace to between 60 and 78% of the full previous rise. It doesn't matter much what is happening or published once wave 1 tops they all do pretty much the same thing and whilever it is in a positive bent and the market is reasonably stable or rising, it will do that regardless. The only question is what will be the trigger. In this case it was started with 112, and it doesn't matter what they said in the report today it would have continued regardless. As it is, a whole bunch of the analysts disagree with your collective "expert" opinions, and it is the analysts for the funds that really set the prices as they are the only ones with suffucient funds to move the market over the medium term, the algos will do their thing in the short to medium term once they get a trigger movement in the market at large that they can use tyo overcome the previous momentum. So today, and for the next few days it goes down until around 260 or 245 (depending on whether the algos are looking for the 61% or 78% fib and then it starts wave 3 riding the rising momentum. With the size of wave 1, wave 3 is going to be huge. There was literally nothing on the downside in that report that was not reasonably expected and the surprises were to the upside, so I wouldn't be surprised if the 61% fib is where it turns. No one who actually knew anything about the company was expecting anything out of 112 because the phase 2 results indicated that and they literally said it ages ago, and I, at least, am not expecting Vifor to be doing much for a year more or so, although others might have been more hopeful. CSL has a good history in acquisitions which often start a bit shakily and take a couple of years to bloom.

In short, IMO, the down movement is overdue on this rise and will continue a tiny bit more and has jack-all to do with the fundamentals and everything to do with crowd behaviour and share movement cycles cemented into the system by algo traders. Fundamentals which are generally strong, and financials which are also strong will set the longer term targets for those algos while the short term targets are just the traders' normal cycles. The next wave is bigger than the first - at least 160% of the first wave.

Here a sample of the assessment of the results from those that actually influence the market rather than just the HC fish-bowl - it doesn't make the right, but does mean they are more likely to be expressing the market as they have a wider more powerful audience:

DJ UBS Sees Mixed Bag in CSL's Half-Year Results -- Market Talk

Analysts at UBS say CSL's half-year results included a beat for immunoglobulin
sales and decreasing plasma donor costs, but that tempered near-term expectations for
iron-deficiency and nephrology unit Vifor could "take the shine off to an extent."
Revenue and underlying profit figures were in line with expectations, while underlying
gross margin was ahead of consensus, says UBS, which is bullish on CSL. Overall, UBS says
the results were in line with expectations. But investors appear a bit pessimistic, as
CSL shares were down about 3.6% in recent trade at A$279.60.

Jarden Research: Target 298 down from 316 - keeps overweight

Macquarie: Target 317.5